Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
$3.82
-3.0%
$8.06
$3.21
$4,680.00
$3.05M2.39122,195 shs815,940 shs
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
$0.00
$0.00
$0.00
$710K-0.21127,366 shsN/A
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
$3.83
+0.8%
$3.90
$2.35
$19.32
$2.26M0.36554,432 shs75,804 shs
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$3.85
-1.8%
$3.54
$2.85
$29.44
$2.83M-0.07112,931 shs277 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
+19.39%+13.22%-51.06%-76.76%-99.91%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00%0.00%0.00%-50.00%0.00%
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
-4.52%-20.17%+21.23%-26.26%-79.44%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
+3.43%+3.98%+9.19%+26.45%-70.96%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
0.7316 of 5 stars
0.04.00.00.03.60.00.0
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
0.4853 of 5 stars
0.02.00.00.02.91.70.0
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
4.00
Strong BuyN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00
N/AN/AN/A
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
0.00
N/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
N/AN/AN/AN/A($0.62) per shareN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/A
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
N/AN/AN/AN/A$0.83 per shareN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$4.98M0.57N/AN/A($20.31) per share-0.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
-$540K-$534.48N/AN/AN/AN/A-328.67%N/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
-$5M-$13.11N/AN/AN/A-308.97%-228.73%8/12/2025 (Estimated)
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
-$13.42MN/A0.00N/AN/AN/A-424.18%6/5/2025 (Estimated)

Latest NPHC, PTIX, CDT, and QLGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
N/A-$19.80N/A-$1.32N/AN/A
5/13/2025Q1 2025
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
N/A-$2.75N/A-$2.75N/AN/A
3/31/2025Q4 2024
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
N/A-$3.36N/A-$0.24N/AN/A
3/28/2025Q4 2024
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
N/A-$304.95N/A-$20.33N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
N/AN/AN/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/A
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
N/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
N/A
0.12
0.12
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/A
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
N/A
1.80
1.80
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/A
0.52
0.52

Institutional Ownership

CompanyInstitutional Ownership
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
3.29%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/A
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
7.97%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
3.18%

Insider Ownership

CompanyInsider Ownership
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
4.05%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
61.50%
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
35.00%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
1.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Conduit Pharmaceuticals Inc. stock logo
CDT
Conduit Pharmaceuticals
3798,000710,000Not Optionable
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
47.10 billion2.73 billionNot Optionable
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
2589,0004.71 millionNot Optionable
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
50736,000723,000Not Optionable

Recent News About These Companies

Qualigen Therapeutics to participate in next funding round for NanoSynex
Qualigen to participate in next funding round for NanoSynex
Qualigen announces $4.5M private placement of Preferred Shares

New MarketBeat Followers Over Time

Media Sentiment Over Time

Conduit Pharmaceuticals stock logo

Conduit Pharmaceuticals NASDAQ:CDT

$3.82 -0.12 (-3.05%)
As of 11:09 AM Eastern

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Nutra Pharma stock logo

Nutra Pharma OTCMKTS:NPHC

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

Protagenic Therapeutics stock logo

Protagenic Therapeutics NASDAQ:PTIX

$3.83 +0.03 (+0.79%)
As of 11:03 AM Eastern

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Qualigen Therapeutics stock logo

Qualigen Therapeutics NASDAQ:QLGN

$3.85 -0.07 (-1.79%)
As of 10:32 AM Eastern

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.